Overview of the Mechanism of Action of TAR-200 in Patients With BCG-Unresponsive High-Risk NMIBC

Opinion
Video

The TAR-200 treatment for BCG-unresponsive NMIBC works through a catheter-placed intravesical device that elutes gemcitabine over 3 weeks, providing a high complete response rate of 77% in early testing, likely due to the sustained release mechanism.

Related Videos
Rohit Gosain, MD; Rahul Gosain, MD; and Tian Zhang, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Tian Zhang, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Tian Zhang, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Tian Zhang, MD, presenting slides
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Related Content